172 related articles for article (PubMed ID: 37330302)
1. Identification of prognostic melatonin-related lncRNA signature in tumor immune microenvironment and drug resistance for breast cancer.
Gao SC; Wu MD; Zhang XX; Liu YF; Wang CL
Asian J Surg; 2023 Sep; 46(9):3529-3541. PubMed ID: 37330302
[TBL] [Abstract][Full Text] [Related]
2. A mitochondrial function-related LncRNA signature predicts prognosis and immune microenvironment for breast cancer.
Wang Y; Gao S; Xu Y; Tang Z; Liu S
Sci Rep; 2023 Mar; 13(1):3918. PubMed ID: 36890266
[TBL] [Abstract][Full Text] [Related]
3. Development of the expression and prognostic significance of m
Xu G; Li C; Di Z; Yang Y; Liang L; Yuan Q; Yang Q; Dong X; Xu S; Wu G
Cancer Med; 2023 Mar; 12(6):7667-7681. PubMed ID: 36464884
[TBL] [Abstract][Full Text] [Related]
4. Multi-omics analysis revealing a senescence-relevant lncRNAs signature for the assessment of response to immunotherapy for breast cancer.
Yu Z; Zhu Y; Ji J
Medicine (Baltimore); 2023 Jul; 102(28):e34287. PubMed ID: 37443486
[TBL] [Abstract][Full Text] [Related]
5. A prognostic model based on immune-related long noncoding RNAs for patients with epithelial ovarian cancer.
Peng Y; Wang H; Huang Q; Wu J; Zhang M
J Ovarian Res; 2022 Jan; 15(1):8. PubMed ID: 35031063
[TBL] [Abstract][Full Text] [Related]
6. Exploration of epithelial-mesenchymal transition-related lncRNA signature and drug sensitivity in breast cancer.
Li C; Zheng L; Xu G; Yuan Q; Di Z; Yang Y; Dong X; Hou J; Wu G
Front Endocrinol (Lausanne); 2023; 14():1154741. PubMed ID: 37538794
[TBL] [Abstract][Full Text] [Related]
7. A Novel Pyroptosis-Associated Long Non-coding RNA Signature Predicts Prognosis and Tumor Immune Microenvironment of Patients With Breast Cancer.
Ping L; Zhang K; Ou X; Qiu X; Xiao X
Front Cell Dev Biol; 2021; 9():727183. PubMed ID: 34616734
[No Abstract] [Full Text] [Related]
8. Identification of Five Immune-Related lncRNAs Predicting Survival and Tumor Microenvironment Characteristics in Breast Cancer.
Xiao R; Yang M; Tan Y; Ding R; Li D
Comput Math Methods Med; 2021; 2021():6676692. PubMed ID: 33727952
[TBL] [Abstract][Full Text] [Related]
9. Immune-related lncRNAs as predictors of survival in breast cancer: a prognostic signature.
Ma W; Zhao F; Yu X; Guan S; Suo H; Tao Z; Qiu Y; Wu Y; Cao Y; Jin F
J Transl Med; 2020 Nov; 18(1):442. PubMed ID: 33225954
[TBL] [Abstract][Full Text] [Related]
10. A Novel Necroptosis-Associated lncRNA Signature Can Impact the Immune Status and Predict the Outcome of Breast Cancer.
Zhang X; Zhang X; Li G; Hao Y; Liu L; Zhang L; Chen Y; Wu J; Wang X; Yang S; Xu S
J Immunol Res; 2022; 2022():3143511. PubMed ID: 35578667
[TBL] [Abstract][Full Text] [Related]
11. Construction and validation of a cuproptosis-related five-lncRNA signature for predicting prognosis, immune response and drug sensitivity in breast cancer.
Li C; Zhang Y
BMC Med Genomics; 2023 Jul; 16(1):158. PubMed ID: 37422644
[TBL] [Abstract][Full Text] [Related]
12. Identification and validation of endocrine resistance-related and immune-related long non-coding RNA (lncRNA) signatures for predicting endocrinotherapy response and prognosis in breast cancer.
Yang M; Sun Y; Ji H; Zhang Q
Ann Transl Med; 2022 Dec; 10(24):1399. PubMed ID: 36660659
[TBL] [Abstract][Full Text] [Related]
13. An eight-lncRNA signature predicts survival of breast cancer patients: a comprehensive study based on weighted gene co-expression network analysis and competing endogenous RNA network.
Sun M; Wu D; Zhou K; Li H; Gong X; Wei Q; Du M; Lei P; Zha J; Zhu H; Gu X; Huang D
Breast Cancer Res Treat; 2019 May; 175(1):59-75. PubMed ID: 30715658
[TBL] [Abstract][Full Text] [Related]
14. Angiogenesis-related lncRNAs predict the prognosis signature of stomach adenocarcinoma.
Han C; Zhang C; Wang H; Li K; Zhao L
BMC Cancer; 2021 Dec; 21(1):1312. PubMed ID: 34876056
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer.
Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M
Front Immunol; 2022; 13():891175. PubMed ID: 35990668
[TBL] [Abstract][Full Text] [Related]
16. Development of a novel five-lncRNA prognostic signature for predicting overall survival in elderly patients with breast cancer.
Luo Y; Zhang Y; Wu YX; Li HB; Shen D; Che YQ
J Clin Lab Anal; 2022 Jan; 36(1):e24172. PubMed ID: 34894405
[TBL] [Abstract][Full Text] [Related]
17. A four-gene signature in the tumor microenvironment that significantly associates with the prognosis of patients with breast cancer.
Wang J; Yang Z; Zhang C; Ouyang J; Zhang G; Wu C
Gene; 2020 Nov; 761():145049. PubMed ID: 32791092
[TBL] [Abstract][Full Text] [Related]
18. A six-gene-based signature for breast cancer radiotherapy sensitivity estimation.
Chen X; Zheng J; Zhuo ML; Zhang A; You Z
Biosci Rep; 2020 Dec; 40(12):. PubMed ID: 33179733
[TBL] [Abstract][Full Text] [Related]
19. A novel cuproptosis-related lncRNA signature predicts the prognosis and immune landscape in bladder cancer.
Bai Y; Zhang Q; Liu F; Quan J
Front Immunol; 2022; 13():1027449. PubMed ID: 36451815
[TBL] [Abstract][Full Text] [Related]
20. A robust signature of immune-related long non-coding RNA to predict the prognosis of bladder cancer.
Lai C; Wu Z; Li Z; Yu H; Li K; Tang Z; Liu C; Xu K
Cancer Med; 2021 Sep; 10(18):6534-6545. PubMed ID: 34374227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
